

## 文献

アスタリスク (\*) をつけたものは、本システマティックレビューでの評価対象論文として掲載した（したがって本文に引用していないものを含む）。

- \*Aglietta, M., Barone, C., Sawyer, M. B., Moore, M. J., Miller, W. H., Jr., Bagala, C. Leone, F. (2014). A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. *Ann Oncol*, 25(9), 1750-1755. doi: 10.1093/annonc/mdu205.
- \*Ansell, S. M., Hurvitz, S. A., Koenig, P. A., LaPlant, B. R., Kabat, B. F., Fernando, D., Timmerman, J. M. (2009). Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. *Clin Cancer Res*, 15(20), 6446-6453. doi: 10.1158/1078-0432.ccr-09-1339.
- \*Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y. B., Gordon, L. I. (2013). Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. *J Clin Oncol*, 31(33), 4199-4206. doi: 10.1200/jco.2012.48.3685. (accessed 24th Jun 2016)
- \*Atkins, M., Kudchadkar, R., Sznol, M., McDermott, D., Lotem, M., Schachter, J., Sosman, J. (2014). Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. *JOURNAL OF CLINICAL ONCOLOGY*, 32 (15 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/163/CN-01060163/frame.html> (accessed 24th Jun 2016)
- \*Balmanoukian, A., Rizvi, N., Garon, E., Patnaik, A., Gandhi, L., Leighl, N., Hui, R. (2014). Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). *International Journal of Radiation Oncology Biology Physics*, 90(5 suppl. 1), S1-S2. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/085/CN-01088085/frame.html> (accessed 24th Jun 2016)
- Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., Schrag, D. (2009). Adverse

- symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst*, 101(23), 1624-1632. doi:10.1093/jnci/djp386.
- Basch, E. (2010). The missing voice of patients in drug-safety reporting. *N Engl J Med*, 362(10), 865-869. doi:10.1056/NEJMp0911494.
- Basch, E., Bennett, A., & Pietanza, M. C. (2011). Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events *J Natl Cancer Inst* (Vol. 103, pp. 1808-1810). United States.
- \*Bendell, J., Powderly, J., Lieu, C., Eckhardt, S., Hurwitz, H., Hochster, H., Pishvaian, M. (2015). Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). *JOURNAL OF CLINICAL ONCOLOGY*, 33(3 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/822/CN-01087822/frame.html> (accessed 24th Jun 2016)
- \*Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*, 373(17), 1627-1639. doi: 10.1056/NEJMoa1507643.
- \*Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*, 373(2), 123-135. doi: 10.1056/NEJMoa1504627.
- \*Calabro, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., Maio, M. (2013). Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. *Lancet Oncol*, 14(11), 1104-1111. doi: 10.1016/s1470-2045(13)70381-4.
- \*Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., Maio, M. (2015). Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study. *The Lancet Respiratory Medicine*, 3(4), 301-309.
- \*Camacho, L. H., Antonia, S., Sosman, J., Kirkwood, J. M., Gajewski, T. F., Redman, B., . . . Ribas, A. (2009). Phase I/II trial of tremelimumab in patients with metastatic

- melanoma. *J Clin Oncol*, 27(7), 1075-1081. doi: 10.1200/jco.2008.19.2435.
- Cella, D., Davis, M. P., Négrier, S., Figlin, R. A., Michaelson, M. D., Bushmakin, A. G., Motzer, R. J. (2014). Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. *Cancer*, 120(12), 1871-1880. doi:10.1002/cncr.28660.
- \*Chung, K. Y., Gore, I., Fong, L., Venook, A., Beck, S. B., Dorazio, P., Saltz, L. B. (2010). Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol*, 28(21), 3485-3490. doi: 10.1200/jco.2010.28.3994.
- \*Di Giacomo, A. M., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., Maio, M. (2012). Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. *Lancet Oncol*, 13(9), 879-886. doi: 10.1016/s1470-2045(12)70324-8.
- Dirven, L., Taphoorn, M. J., Reijneveld, J. C., Blazeby, J., Jacobs, M., Pusic, A., EORTC Quality of Life Group (2014). The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. *Eur J Cancer*, 50(14), 2432-2448. doi:10.1016/j.ejca.2014.06.016.
- \*Drake, C., Kwon, E., Fizazi, K., Bossi, A., Eertwegh, A., Logothetis, C., Gerritsen, W. (2014). Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). *JOURNAL OF CLINICAL ONCOLOGY*, 32(4 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/530/CN-01062530/frame.html> (accessed 24th Jun 2016)
- Efficace, F., Jacobs, M., Pusic, A., Greimel, E., Piciocchi, A., Kieffer, J. M., EORTC Quality of Life Group Patient Reported Outcome Measurements Over Time In Oncology-PROMOTION Registry. (2014). Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making. *Eur J Cancer*, 50(11), 1925-1941. doi:10.1016/j.ejca.2014.04.005.
- \*Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt,

- H., Testori, A. (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol*, 16(5), 522-530. doi: 10.1016/s1470-2045(15)70122-1.
- Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D., Cortazar, P., Schnipper, L. E. (2014). American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*, 32(12), 1277-1280. doi:10.1200/JCO.2013.53.8009.
- FDA (U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health). (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. *Health Qual Life Outcomes*, 4, 79. doi:10.1186/1477-7525-4-79.
- \*Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Brahmer, J. R. (2015). Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*, 33(18), 2004-2012. doi: 10.1200/jco.2014.58.3708.
- \*Gibney, G. T., Kudchadkar, R. R., DeConti, R. C., Thebeau, M. S., Czupryn, M. P., Tetteh, L., Weber, J. S. (2015). Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. *Clin Cancer Res*, 21(4), 712-720. doi: 10.1158/1078-0432.ccr-14-2468.
- \*Haanen, J. B., Hodi, F. S., O'Day, S. J., McDermott, D. F., Robert, C., Schadendorf, D., Urba, W. J. (2010). Ipilimumab improves overall survival in patients with previously treated, advanced melanoma: Long-term survival results from a phase III trial. *Annals of Oncology*, 21, viii402.
- \*Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Konishi, I. (2015). Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. *JOURNAL OF CLINICAL ONCOLOGY*, 33(34),

4015-4022.

- \*Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Ribas, A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med*, 369(2), 134-144. doi: 10.1056/NEJMoa1305133.
- \*Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Berman, D. (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. *J Transl Med*, 9(1).
- \*Hammers, H., Plimack, E., Infante, J., Ernstoff, M., Rini, B., McDermott, D., Amin, A. (2014). Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). *JOURNAL OF CLINICAL ONCOLOGY*, 32(15 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/899/CN-01055899/frame.html> (accessed 24th Jun 2016)
- \*Hatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. *Health Qual Life Outcomes*, 12, 140. doi: 10.1186/s12955-014-0140-1.
- \*Herbst, R., Gandara, D., Hirsch, F., Redman, M., LeBlanc, M., Mack, P., Papadimitrakopoulou, V. (2015). Lung Master Protocol (Lung-MAP) - A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. *Clinical Cancer Research*, 21(7 // (NCI) \*Genentech\* // R01CA155196 (NIH) \*Genentech\* // U10CA180819 (NIH) \*Genentech\* // U10CA180888 (NIH) \*Genentech\* // \*Genentech\* // (FNIH) \*Genentech\*), 1514-1524. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/486/CN-01079486/frame.html> doi:10.1158/1078-0432.CCR-13-3473 (accessed 24th Jun 2016)
- \*Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*, 387: 1540-1550.

- \*Hersh, E. M., O'Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Weber, J. S. (2011). A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. *Invest New Drugs*, 29(3), 489-498. doi: 10.1007/s10637-009-9376-8.
- Higgins, JPT, & S, G. (2011). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. In H. JPT & G. S (Eds.), *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration*. Retrieved from <http://www.cochrane-handbook.org>. (accessed 24th Jun 2016)
- \*Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., McDermott, D. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. *Cancer Immunol Res*, 2(7), 632-642. doi: 10.1158/2326-6066.cir-14-0053.
- \*Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Kirkwood, J. M. (2014). Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. *Jama*, 312(17), 1744-1753. doi: 10.1001/jama.2014.13943.
- \*Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*, 363(8), 711-723. doi: 10.1056/NEJMoa1003466.
- \*Horinouchi, H., Yamamoto, N., Fujiwara, Y., Sekine, I., Nokihara, H., Kubota, K., Tamura, T. (2015). Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. *Invest New Drugs*, 33(4), 881-889.
- \*Jamal, R., Belanger, K., Friedmann, J., Ayoub, J.-P., Cocolakis, E., Kazemi, S., Miller, W. (2014). A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). *JOURNAL OF CLINICAL ONCOLOGY*, 32(15 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/157/CN-01060157/frame.html> (accessed 24th Jun 2016)
- \*Jochems, C., Tucker, J. A., Tsang, K. Y., Madan, R. A., Dahut, W. L., Liewehr, D. J.,

- Schlom, J. (2014). A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. *Cancer Immunol Immunother*, 63(4), 407-418. doi: 10.1007/s00262-014-1524-0.
- \*Kindler, H. L., Di Pietro, A., Robbins, P. B., Hong, S., Shalabi, A., Ibrahim, R., Maio, M. (2013). A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma. *Journal of Thoracic Oncology*, 8, S942.
- \*Kirkwood, J. M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., Bulanhagui, C. A. (2010). Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clin Cancer Res*, 16(3), 1042-1048. doi: 10.1158/1078-0432.ccr-09-2033.
- Kotronoulas, G., Kearney, N., Maguire, R., Harrow, A., Di Domenico, D., Croy, S., & Macgillivray, S. (2014). What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. *J Clin Oncol*, 32(14), 1480-1501. doi:10.1200/JCO.2013.53.5948.
- Kourie HR, Awada G, Awada AH. (2016). Learning from the "tsunami" of immune checkpoint inhibitors in 2015. *Crit Rev Oncol Hematol*, 101: 213-20.
- \*Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J., Gerritsen, W. R. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*, 15(7), 700-712. doi: 10.1016/s1470-2045(14)70189-5.
- \*Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Wolchok, J. D. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*, 373(1), 23-34. doi: 10.1056/NEJMoa1504030.
- \*Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Laheru, D. A. (2013). Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. *J Immunother*, 36(7), 382-389. doi: 10.1097/CJI.0b013e31829fb7a2.

- \*Lebbé, C., McDermott, D. F., Robert, C., Lorigan, P., Ottensmeier, C. H., Wolchok, J., Weber, J. S. (2010). Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: Subgroup analyses from a phase III trial. *Annals of Oncology*, 21, viii401.
- \*Lebbe, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., Wolchok, J. D. (2014). Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. *Ann Oncol*, 25(11), 2277-2284. doi: 10.1093/annonc/mdu441.
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*, 339, b2700.
- \*Lynch, T., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Reck, M. (2011). Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in non-small cell lung cancer: Analysis by baseline histology in a phase 2 trial. *Journal of Thoracic Oncology*, 6(6 suppl. 2), S660-s661.  
<http://onlinelibrary.wiley.com/doi/10.1002/jco.21138> (accessed 24th Jun 2016)
- \*Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Reck, M. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol*, 30(17), 2046-2054. doi: 10.1200/jco.2011.38.4032.
- \*Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Gulley, J. L. (2012). Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. *Lancet Oncol*, 13(5), 501-508. doi: 10.1016/s1470-2045(12)70006-2.
- \*Maio, M., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Testori, A., Wolchok, J. (2013). Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. *EUROPEAN JOURNAL OF CANCER*, 49,



S857. <http://onlinelibrary.wiley.com/doi/10.1016/S0959-8049%2813%2970065-0> (accessed 24th Jun 2016)

- \*Maio, M., Grob, J. J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., Wolchok, J. D. (2015). Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *J Clin Oncol*, 33(10), 1191-1196. doi: 10.1200/jco.2014.56.6018.
- \*Maio, M., Scherpereel, A., Di Pietro, A., Vasey, P., Tsao, A. S., Calabrò, L., Kindler, H. L. (2014). Randomized, double-blind, placebo-controlled study of tremelimumab for second-and third-line treatment of unresectable pleural or peritoneal mesothelioma. *JOURNAL OF CLINICAL ONCOLOGY*, 32(15).
- \*Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Rosenberg, S. A. (2005). Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. *Ann Surg Oncol*, 12(12), 1005-1016. doi: 10.1245/aso.2005.03.536.
- \*Margolin, K. (2012). Ipilimumab in a phase ii trial of melanoma patients with brain metastases. *Oncolmmunology*, 1(7), 1197-1199.
- \*Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Hodi, F. S. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol*, 13(5), 459-465. doi: 10.1016/s1470-2045(12)70090-6.
- \*McDermott, D., Haanen, J., Chen, T. T., Lorigan, P., & O'Day, S. (2013). Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). *Ann Oncol*, 24(10), 2694-2698. doi: 10.1093/annonc/mdt291.
- \*McDermott, D. F., Drake, C. G., Sznol, M., Choueiri, T. K., Powderly, J. D., Smith, D. C., . . . Atkins, M. B. (2015). Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *J Clin Oncol*, 33(18), 2013-2020. doi: 10.1200/jco.2014.58.1041.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The, P. G. (2009). Preferred Reporting

Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*, 6(7), e1000097. doi:10.1371/journal.pmed.1000097.

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*, 361(10), 947-957. doi:10.1056/NEJMoa0810699.

\*Motzer, R., Rini, B., McDermott, D., Redman, B., Kuzel, T., Harrison, M., Hammers, H. (2014). Patients with PD-L1 expression by IHC 1/2/3 demonstrated evidence of increased activity. Durable responses were observed in mRCC patients, warranting further study Randomized, doseranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC). *BJU Int*, 114, 12-13.

<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/193/CN-01074193/frame.html> doi:10.1111/bju.12941/abstract (accessed 24th Jun 2016)

\*Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*, 373(19), 1803-1813. doi: 10.1056/NEJMoa1510665.

\*Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Hammers, H. J. (2015). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. *J Clin Oncol*, 33(13), 1430-1437. doi: 10.1200/jco.2014.59.0703.

NCI (Healthcare Delivery Research Program, Division of cancer control and population sciences, National Cancer Institute). (2014). Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Overview. Retrieved from <http://healthcaredelivery.cancer.gov/pro-ctcae/> Retrieved from <https://wiki.nci.nih.gov/pages/viewpage.action?pageId=10857328> (accessed 24th Jun 2016)

\*Nct. (2015). A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer (SCCHN) Patients. *Clinicaltrials.gov* [[www.clinicaltrials.gov](http://www.clinicaltrials.gov)]. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/455/CN->

01104455/frame.html (accessed 24th Jun 2016)

- \*Nct. (2016). A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122). Clinicaltrials.gov [www.clinicaltrials.gov].  
<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/491/CN-01104491/frame.html> (accessed 24th Jun 2016)
- \*O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Wolchok, J. D. (2010a). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. *Ann Oncol*, 21(8), 1712-1717. doi: 10.1093/annonc/mdq013.
- \*O'Day, S. J., McDermott, D. F., Urba, W. J., Wolchok, J. D., Robert, C., Haanen, J. B., Hodi, F. S. (2010b). Ipilimumab improves overall survival in previously treated, advanced melanoma patients with good and poor prognostic factors. *Journal of Immunotherapy*, 33(8), 905-906.
- Pakhomov, S. V., Jacobsen, S. J., Chute, C. G., & Roger, V. L. (2008). Agreement between patient-reported symptoms and their documentation in the medical record. *American Journal of Managed Care*, 14, 530-539.
- \*Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Tolcher, A. W. (2015). Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. *Clinical Cancer Research*, 21(19), 4286-4293.
- \*Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Hodi, F. S. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med*, 372(21), 2006-2017. doi: 10.1056/NEJMoa1414428.
- \*Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loria, Y., Cruz, C., Vogelzang, N. J. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature*, 515(7528), 558-562. doi: 10.1038/nature13904.
- \*Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Thistlethwaite, F. C. (2010). Modulation of lymphocyte regulation for cancer therapy: a phase II trial

of tremelimumab in advanced gastric and esophageal adenocarcinoma. *Clin Cancer Res*, 16(5), 1662-1672. doi: 10.1158/1078-0432.ccr-09-2870.

- \*Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Lynch, T. J. (2013). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol*, 24(1), 75-83. doi: 10.1093/annonc/mds213.
- Reuben, D. B., & Tinetti, M. E. (2012). Goal-oriented patient care--an alternative health outcomes paradigm. *N Engl J Med*, 366(9), 777-779. doi:10.1056/NEJMp1113631.
- \*Revicki, D. A., van den Eertwegh, A. J., Lorigan, P., Lebbe, C., Linette, G., Ottensmeier, C. H., . . . Kotapati, S. (2012). Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. *Health Qual Life Outcomes*, 10, 66. doi: 10.1186/1477-7525-10-66.
- RevMan (Review Manager) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- \*Rexer, H. (2015). Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Keynote 045) – AP 48/15 der AUO. *Urologe*, 54(9), 1287-1290.
- \*Rexer, H. (2015). Therapy of untreated local advanced or metastatic renal cell carcinoma: Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 – AN 36/15 of the AUO). *Urologe*, 54(10), 1443-1445.
- \*Ribas, A., Chesney, J. A., Gordon, M. S., Abernethy, A. P., Logan, T. F., Lawson, D. H., Gonzalez, R. (2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. *J Transl Med*, 10, 236. doi: 10.1186/1479-5876-10-236.
- \*Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., Hauschild, A. (2013). Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol*, 31(5), 616-

622. doi: 10.1200/jco.2012.44.6112.

- \*Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Daud, A. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol*, 16(8), 908-918. doi: 10.1016/s1470-2045(15)00083-2.
- \*Rini, B. I., Stein, M., Shannon, P., Eddy, S., Tyler, A., Stephenson, J. J., Jr., Gordon, M. (2011). Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. *Cancer*, 117(4), 758-767. doi: 10.1002/cncr.25639.
- \*Rizvi, N., Antonia, S., Shepherd, F., Chow, L., Goldman, J., Shen, Y., Gettinger, S. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. *International Journal of Radiation Oncology Biology Physics*, 90(5 suppl. 1), S32.  
<http://onlinelibrary.wiley.com/doi/10.1002/ijro.12101> (accessed 24th Jun 2016)
- \*Rizvi, N. A., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Ramalingam, S. S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol*, 16(3), 257-265. doi: 10.1016/s1470-2045(15)70054-9.
- \*Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Ascierto, P. A. (2015a). Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*, 372(4), 320-330. doi: 10.1056/NEJMoa1412082.
- \*Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Daud, A. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet*, 384(9948), 1109-1117. doi: 10.1016/s0140-6736(14)60958-2.
- \*Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Ribas, A. (2015b). Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*, 372(26), 2521-2532. doi: 10.1056/NEJMoa1503093.

- \*Robert, C., Schadendorf, D., Messina, M., Hodi, F. S., & O'Day, S. (2013). Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. *Clin Cancer Res*, 19(8), 2232-2239. doi: 10.1158/1078-0432.ccr-12-3080.
- \*Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Wolchok, J. D. (2011a). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med*, 364(26), 2517-2526. doi: 10.1056/NEJMoa1104621.
- \*Robert, C., Thomas, L., Garbe, C., Lebbe, C., Baurain, J., Testori, A., Wolchok, J. (2011b). Phase 3 randomized study of Ipilimumab (IPI) plus dacarbazine (DTIC) vs DTIC alone as first line treatment in patients with unresectable stage III or IV Melanoma. *EUROPEAN JOURNAL OF CANCER*, 47, S657-s658.  
<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/143/CN-01021143/frame.html> doi:10.1016/S0959-8049%2811%2972527-8
- \*Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Rosenberg, S. A. (2010). Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. *Journal of Immunotherapy*, 33(8), 828-833.
- \*Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., Prieto, J. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol*, 59(1), 81-88. doi: 10.1016/j.jhep.2013.02.022.
- \*Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., Weber, J. S. (2011). Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. *Clin Cancer Res*, 17(4), 896-906. doi: 10.1158/1078-0432.ccr-10-2463.
- Schulz, K. F., Altman, D. G., Moher, D., & Group, C. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials*, 11, 32. doi:10.1186/1745-6215-11-32.
- \*Sherrill, B., Wang, J., Kotapati, S., & Chin, K. (2013). Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. *Br J Cancer*, 109(1), 8-13. doi: 10.1038/bjc.2013.298.

- Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., Hausheer, F. H. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. *Support Care Cancer*, 17(12), 1483-1491. doi:10.1007/s00520-009-0613-7.
- \*Singh, H., Madan, R. A., Dahut, W. L., Strauss, J., Rauckhorst, M., McMahon, S., Gulley, J. L. (2015). Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. *JOURNAL OF CLINICAL ONCOLOGY*, 33(15).
- \*Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Beer, T. M. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol*, 24(7), 1813-1821. doi: 10.1093/annonc/mdt107.
- \*Small, E., Higano, C., Tchekmedyian, N., Sartor, O., Stein, B., Young, R., Lowy, I. (2006). Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. *ASCO Meeting Abstracts*, 24(18\_suppl), 4609.
- \*Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Kirkwood, J. M. (2012). Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. *J Clin Oncol*, 30(3), 322-328. doi: 10.1200/jco.2011.37.5394.
- Tate, W. R., & Skrepnek, G. H. (2015). Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer. *Psychooncology*, 24(3), 253-261. doi:10.1002/pon.3595.
- \*Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I. G., Ridolfi, R., Weber, J. S. (2012). Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. *J Immunother*, 35(1), 73-77. doi: 10.1097/CJI.0b013e31823735d6.
- \*Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*, 366(26), 2443-2454. doi: 10.1056/NEJMoa1200690.

- \*Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Hodi, F. S. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol*, 32(10), 1020-1030. doi: 10.1200/jco.2013.53.0105.
- Trotti, A., Colevas, A. D., Setser, A., & Basch, E. (2007). Patient-reported outcomes and the evolution of adverse event reporting in oncology. *J Clin Oncol*, 25, 5121-5127. doi:10.1200/JCO.2007.12.4784.
- \*Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D., Soulieres, D., Domchek, S. M. (2010). Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. *Clin Cancer Res*, 16(13), 3485-3494. doi: 10.1158/1078-0432.ccr-10-0505.
- \*Weber, J., Hamid, O., Amin, A., O'Day, S., Masson, E., Goldberg, S. M., Wolchok, J. D. (2013). Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. *Cancer Immun*, 13, 7.
- \*Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., O'Day, S. J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clin Cancer Res*, 15(17), 5591-5598. doi: 10.1158/1078-0432.ccr-09-1024.
- \*Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*, 16(4), 375-384. doi: 10.1016/s1470-2045(15)70076-8.
- \*Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Chen, Y. A. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. *J Clin Oncol*, 31(34), 4311-4318. doi: 10.1200/jco.2013.51.4802.



- \*Weber, J. S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Hersh, E. (2008). Phase I/II study of ipilimumab for patients with metastatic melanoma. *J Clin Oncol*, 26(36), 5950-5956. doi: 10.1200/jco.2008.16.1927.
- \*Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Neelapu, S. S. (2014). Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol*, 15(1), 69-77. doi: 10.1016/s1470-2045(13)70551-5.
- Willke, R. J., Burke, L. B., & Erickson, P. (2004). Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. *Control Clin Trials*, 25(6), 535-552. doi:10.1016/j.cct.2004.09.003.
- \*Wolchok, J., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Robert, C. (2011). Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. *JOURNAL OF CLINICAL ONCOLOGY*, 29(18 suppl. 1). <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/354/CN-01034354/frame.html> (accessed 24th Jun 2016)
- \*Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., . . . Sznol, M. (2013). Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*, 369(2), 122-133. doi: 10.1056/NEJMoa1302369.
- \*Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Lebbe, C. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol*, 11(2), 155-164. doi: 10.1016/s1470-2045(09)70334-1.
- \*Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Lebbe, C. (2013). Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. *Ann Oncol*, 24(8), 2174-2180. doi: 10.1093/annonc/mdt161.
- Yamaguchi, T., Iwase, S., Goto, Y., Tsuboi, M., Yamamoto, D., Odagiri, H., Basch, E. (2013). 生物統計学 臨床試験における QOL と経済的評価 PRO-CTCAE の日本版に関する開発プログラム(Biostatistics Quality of Life in Clinical Trials and Economic

Evaluation). 薬理と治療, 41, S79-S82.

\*Yang, J., Beck, K., Blansfield, J., Tran, K., Lowy, I., & Rosenberg, S. (2005). Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010) [abstract]. Annual Meeting Proceedings of the American Society of Clinical Oncology, 23, 166.

<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/675/CN-00646675/frame.html> (accessed 24th Jun 2016)

\*Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Rosenberg, S. A. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother, 30(8), 825-830. doi: 10.1097/CJI.0b013e318156e47e.

\*Zatloukal, P., Heo, D., Park, K., Kang, J., Butts, C., Bradford, D., Healey, D. (2009). Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract no. 8071]. JOURNAL OF CLINICAL ONCOLOGY, 27(15S Part I), 424.

<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/448/CN-00795448/frame.html> (accessed 24th Jun 2016)

\*Zimmer, L., Eigentler, T. K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., Schadendorf, D. (2015). Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med, 13(1).

\*Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Schadendorf, D. (2015). Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One, 10(3), e0118564. doi: 10.1371/journal.pone.0118564.

福島聡. 免疫チェックポイント阻害剤による有害事象. (2016). 日本臨床免疫学会会誌, 39(1): 30-6.

福田, 治. (2013). 【治療効果の判定基準と臨床試験の endpoint】 QOL がん臨床試験における QOL 評価の問題点. 腫瘍内科, 12(4), 440-449.

- 濱西, 潤., & 小西, 郁. (2014). 【がん免疫抑制・免疫疲弊と新規治療】 免疫チェックポイント PD-1/PD-L1 経路を標的とする新しいがん治療. 癌と化学療法, 41(9), 1071-1076.
- 小林, 和. (2014). 添付文書情報にみる健康関連 QOL の利用 -日米欧三極の利用状況と注目事例紹介-. 日本製薬工業協会 製薬産業政策研究所 政策研ニュース, 41, 1-6.
- 国立研究開発法人国立がん研究センターがん対策情報センター. (2015). 最新がん統計. Retrieved from <http://ganjoho.jp/public/statistics/pub/statistics01.html> (accessed 24th Jun 2016)
- 南, 博., 藤原, 豊., 山崎, 直., & 中村, 健. (2014). 免疫チェックポイント分子を標的とした治療の展開. がん分子標的治療, 12(1), 42-50.
- 日本臨床腫瘍学会. (2016). 抗 PD-1 抗体、ニボルマブ (オプジーボ(R)) の適正な使用について. <http://www.jsmo.or.jp/> (accessed 24th Jun 2016)
- 日本臨床腫瘍学会, 日本糖尿病学会. (2016). 免疫チェックポイント阻害薬に関連した劇症 1 型糖尿病の発症について. <http://www.jsmo.or.jp/> (accessed 24th Jun 2016)
- 日経メディカル. (2014). パイプライン・ウォッチ⑧免疫チェックポイント阻害薬, Vol.9, 24-28.

